Page 4 - Pharmaceutical Companies

Result preview: Domestic biz, easing price pressure to boost pharma margins

Hospitals and Diagnostics revenues to grow 13-15% in Q4

Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline

Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official. The company plans to enhance its presence in the diabetes segment and grow its consumer healthcare business after spinning it off into a new entity while also looking at local production of its various best-in-class products in India. In an interaction with PTI, Sanofi India Managing Director Rodolfo Hrosz stated that the company has embarked on a mission to prepare for an accelerated growth path in the country. "We believe we're under-represented (in India) and we see a significant opportunity right now and in the future as well. The potential of this market is phenomenal," he said. He further said: "We are seeking the route to be better represented ... with a fair share of the Indian pharmaceutical ...

MNCs partner Indian firms to boost market reach in pharmaceutical sector

MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas

Domestic drug firms to witness 8-10% revenue growth in FY25: Report

Revenue growth of leading 25 domestic drug firms is expected to moderate to 8-10 per cent in the next fiscal year, rating agency Icra said on Thursday. The revenue of the companies, which account for 60 per cent of the overall Indian pharmaceutical industry, witnessed an increase of 13-14 per cent in the current fiscal year. Following the high base of 2023-24, the revenue growth momentum from the US and Europe markets is expected to moderate to 8-10 per cent and 7-9 per cent, respectively, Icra said. The markets are expected to witness a year-on-year expansion of 18-20 per cent and 16-18 per cent, respectively, in the current fiscal year, it added. The domestic market, on the other hand, is expected to see a stable growth of 6-8 per cent, while the emerging markets may log an 8-10 per cent rise in FY25, against 16-18 per cent in FY24, the rating agency said. The revenue growth of the sample set companies in the US market in FY24 has been supported by increased new product launches

Govt's new code bars unethical marketing of drugs by pharma firms

Medical representatives barred from using 'inducement' or 'subterfuge' to access healthcare professionals

Sun Pharma recalls around 55,000 bottles of generic medication in US

Sun Pharma is recalling about 55,000 bottles of a generic medication to treat bowel disease in the American market, according to the US Food & Drug Administration (USFDA). As per the latest Enforcement Report by the US health regulator, New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the Mumbai-headquartered drug major, is recalling 54,960 bottles of Mesalamine extended-release capsules in the American market. Mesalamine delayed-release capsules are indicated for the treatment of mild to moderate ulcerative colitis. The affected lot of capsules have been manufactured by Sun Pharmaceutical Industries at its Mohali-based manufacturing plant and distributed in the US market by Sun Pharmaceutical Industries Inc. As per the USFDA, the company has initiated the Class II recall due to "Failed Dissolution Specifications". The company initiated the Class II recall on February 5 this year. As per the USFDA, a class II recall is initiated in a situation in which the use of, or

PLI: Propelling India towards 'atmanirbhar' future in pharma and meditech

The PLI schemes in the pharma-meditech sectors have been a resounding success, and they've heralded a new era for the Indian industry

US FDA approves Eyenovia's eye drops to reduce pain: Formosa Pharma

Eyenovia acquired US commercial rights of the drug last August from Formosa

Advent PE begins merger process of Suven Pharma and Cohance Lifesciences

The merged platform will have mid-30s EBITDA margins, 30 per cent Return on Capital Employed (RoCE) and stable cash flow generation over FY20-23, the statement said

India to have largest R&D presence outside US by 2025: Bristol Myers CEO

Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International

Eris Lifesciences Q3 results: Profit flat at Rs 102 crore, revenue up 16%

On a sequential basis, the company saw a 3.40 per cent decline in revenue along with Profit After Tax (PAT), which also declined by 16.77 per cent

Lupin expands global portfolio with acquisition of assets from Sanofi

The deal involves the acquisition of a portfolio of accretive established products in Europe and Canada

Zydus Lifesciences gets final FDA nod for Darunavir for HIV-1 treatment

According to market research firm IQVIA, Darunavir Tablets, 75 mg, 150 mg, 600 mg, and 800 mg had annual sales of $275 million in the US

Lupin Ltd receives USFDA approval for smoking cessation drug Chantix

The product will be manufactured at Lupin's Pithampur facility in India, the company said in a regulatory filing

Rusan Pharma Invests 300 Crores in New API Facility in MP's Pithampur

New plant to produce 400 MT of APIs, creating more than 300 jobs and enhancing global supply

Cipla concludes 51.18% stake sale in Ugandan subsidiary for $25 million

The sale was executed by Cipla (EU) Limited, UK, and Meditab Holdings Limited, Mauritius, both wholly-owned subsidiaries of Cipla Limited

Aurobindo Pharma arm receives FDA nod for Testosterone Cypionate injection

According to research firm IQVIA, the approved product has an estimated market size of $226.8 million for the twelve months ending August 2023

Sun Pharma recalls 144 bottles of anti-depression drug from US market

Sun Pharmaceutical Industries Inc has recalled 144 bottles of a generic anti-depression medicine from the US market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA). The US-based subsdiary of the Mumbai-headquartered drug company initiated the recall for the affected lot of Bupropion Hydrochloride extended-release tablets due to "failed dissolution specifications,", the US health regulator said in its latest Enforcement Report. The affected lot was manufactured at Sun Pharma's Halol-based plant in Gujarat and was distributed in the US by Sun Pharmaceutical Industries Inc, based in Princeton, New Jersy, it said. Bupropion is a medication commonly used to treat depression. The US-based drug maker initiated the voluntary Class III nationwide (US) recall on October 4 this year. As per the US FDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health ...

BDR Pharma launches generic drug for fungal infections at 1/3rd the cost

Zisavel capsules will be available as 100 mg capsules and will be priced at Rs 7,992 for 7 capsules

New treatment: NMC regulations, albeit diluted, likely to be back soon

Agarwal adds that at a CME the speaking doctor is merely sharing his experience of using a particular molecule; never does he mention a particular brand